Filtered By:
Specialty: Cancer & Oncology
Condition: Heart Failure
This page shows you your search results in order of date. This is page number 3.
Order by Relevance | Date
Total 141 results found since Jan 2013.
Clinical and Prognostic Relevance of Cardiac Wasting in Patients With Advanced Cancer
CONCLUSIONS: Low LV mass is associated with poor functional status and increased all-cause mortality in cancer. These findings provide clinical evidence of cardiac wasting-associated cardiomyopathy in cancer.PMID:37076211 | DOI:10.1016/j.jacc.2023.02.039
Source: Cancer Control - April 20, 2023 Category: Cancer & Oncology Authors: Alessia Lena Ursula Wilkenshoff Sara Hadzibegovic Jan Porthun Lukas R ösnick Ann-Kathrin Fr öhlich Tanja Zeller Mahir Karakas Ulrich Keller Johann Ahn Lars Bullinger Hanno Riess Stuart D Rosen Alexander R Lyon Thomas F L üscher Matthias Totzeck Tienush Source Type: research
Atrial fibrillation, cancer and anticancer drugs
Arch Cardiovasc Dis. 2023 Mar 11:S1875-2136(23)00058-X. doi: 10.1016/j.acvd.2023.02.005. Online ahead of print.ABSTRACTActive cancer is associated with an increased risk of atrial fibrillation (AF), which varies depending on the pre-existing substrate (particularly in older patients), the cancer type and stage, and the anticancer therapeutics being taken. To date, studies have not been able to identify the individual contribution of each factor. During anticancer drug therapy, AF may occur with a frequency of ≈ 15-20% according to several factors, including the patient's baseline cardiovascular toxicity risk and the AF-d...
Source: Cancer Control - March 31, 2023 Category: Cancer & Oncology Authors: Jonaz Font Paul Milliez Alexandre-Boudjema Ouazar Frederikus A Klok Joachim Alexandre Source Type: research
Impact of Cardiovascular Disease on the Death Certificate Diagnosis of Heart Failure, Ischemic Heart Disease, and Cerebrovascular Disease - The Japan Public Health Center-Based Prospective Study
CONCLUSIONS: HF as the UCD was partly explained by CVD. The data imply that most HF deaths reported in vital statistics may be associated with underlying causes other than CVD.PMID:36948630 | DOI:10.1253/circj.CJ-22-0805
Source: Cancer Control - March 22, 2023 Category: Cancer & Oncology Authors: Isao Saito Kazumasa Yamagishi Yoshihiro Kokubo Hiroshi Yatsuya Hiroyasu Iso Norie Sawada Manami Inoue Shoichiro Tsugane Source Type: research
Outcomes of Early Rhythm Control Therapy in Patients With Atrial Fibrillation and a High Comorbidity Burden in Large Real-World Cohorts
CONCLUSIONS: ERC is safe and may be more favorable in a population-based sample of patients with high a comorbidity burden (CHA2DS2-VASc score ≥4).PMID:36942567 | DOI:10.1161/CIRCEP.122.011585
Source: Cancer Control - March 21, 2023 Category: Cancer & Oncology Authors: Jannis Dickow Shinwan Kany Victor Roth Cardoso Patrick T Ellinor Georgios V Gkoutos Holly K Van Houten Paulus Kirchhof Andreas Metzner Peter A Noseworthy Xiaoxi Yao Andreas Rillig Source Type: research
Healthcare systems data in the context of clinical trials - A comparison of cardiovascular data from a clinical trial dataset with routinely collected data
CONCLUSION: Concordance between datasets was lower than anticipated and the HSD used could not straightforwardly replace current trial practices, nor directly identify protocol-defined CVS events. Further work is required to improve the quality of HSD and consider event definitions when designing clinical trials incorporating HSD.PMID:36933612 | DOI:10.1016/j.cct.2023.107162
Source: Clinical Lung Cancer - March 18, 2023 Category: Cancer & Oncology Authors: Archie Macnair Matthew Nankivell Macey L Murray Stuart D Rosen Sally Appleyard Matthew R Sydes Sylvia Forcat Andrew Welland Noel W Clarke Stephen Mangar Howard Kynaston Roger Kockelbergh Abdulla Al-Hasso John Deighan John Marshall Mahesh Parmar Ruth E Lan Source Type: research
Clonal Hematopoiesis of Indeterminate Potential: Current Understanding and Future Directions
This article summarizes the current knowledge about clonal hematopoiesis of indeterminate potential (CHIP), its association with cardiovascular disease (CVD), and other outcomes, pathogenesis, postulated mechanisms of various pathologies, current knowledge gaps, possible targets of intervention, and therapeutic implications.Recent FindingsRecently, a common age-related hematological entity known as CHIP has been identified as the independent risk factor for CVD. CHIP is defined as the presence of clonally expanded blood cells involving leukemogenic mutations without the evidence of malignancy. CHIP is known to increase the...
Source: Current Oncology Reports - March 16, 2023 Category: Cancer & Oncology Source Type: research
Clonal Hematopoiesis and the Heart: a Toxic Relationship
AbstractPurpose of ReviewClonal
hematopoiesis (CH) refers to the expansion of hematopoietic stem cell clones and their cellular progeny due to somatic mutations, mosaic chromosomal alterations (mCAs), or copy number variants which naturally accumulate with age. CH has been linked to increased risk of blood cancers, but CH has also been linked to adverse cardiovascular outcomes.Recent FindingsA combination of clinical outcome studies and mouse models have offered strong evidence that CH mutations either correlate with or cause atherosclerosis, diabetes mellitus, chronic kidney disease, heart failure, pulmonary hypertensi...
Source: Current Oncology Reports - March 15, 2023 Category: Cancer & Oncology Source Type: research
Cardiovascular outcomes among patients with castration-resistant prostate cancer: A comparative safety study using US administrative claims data
CONCLUSIONS: Our study sought to quantify risk of HHF, AMI and ischemic stroke among CRPC patients initiating AAP relative to ENZ within a national administrative claims database. Increased risk for HHF among AAP compared to ENZ users was observed. The difference in myocardial infarction did not attain statistical significance after controlling for residual bias, and no differences were noted in ischemic stroke between the two treatments. These findings confirm labeled warnings and precautions for AAP for HHF and contribute to the comparative real-world evidence on AAP relative to ENZ.PMID:36879362 | DOI:10.1002/pros.24510
Source: Cancer Control - March 6, 2023 Category: Cancer & Oncology Authors: Mitchell M Conover James Weaver Bo Fan Gerhard Leitz Ute Richarz Qing Li Dina Gifkins Source Type: research
Nuts and Cardiovascular Disease Outcomes: A Review of the Evidence and Future Directions
Nutrients. 2023 Feb 11;15(4):911. doi: 10.3390/nu15040911.ABSTRACTNuts are nutrient-rich foods that contain many bioactive compounds that are beneficial for cardiovascular health. Higher consumption of nuts has been associated with a reduced risk of several cardiovascular diseases (CVD) in prospective cohort studies, including a 19% and 25% lower risk of CVD incidence and mortality, respectively, and a 24% and 27% lower risk of coronary heart disease incidence and mortality, respectively. An 18% lower risk of stroke mortality, a 15% lower risk of atrial fibrillation, and a 19% lower risk of total mortality have also been o...
Source: Cancer Control - February 25, 2023 Category: Cancer & Oncology Authors: Andrea J Glenn Dagfinn Aune Heinz Freisling Noushin Mohammadifard Cyril W C Kendall Jordi Salas-Salvad ó David J A Jenkins Frank B Hu John L Sievenpiper Source Type: research
Androgen Deprivation Therapy and Risk of Cardiovascular Disease in Patients With Prostate Cancer Based on Existence of Cardiovascular Risk
CONCLUSIONS: Compared with GnRH agonists, the GnRH antagonist was found to be associated with a decreased risk of HF, specifically among patients with prior CVD. Among those with no prior CVD, the GnRH antagonist was associated with a decreased risk of IHD but an increased risk of arrhythmia.PMID:36791755 | DOI:10.6004/jnccn.2022.7083
Source: Journal of the National Comprehensive Cancer Network : JNCCN - February 15, 2023 Category: Cancer & Oncology Authors: Alice Dragomir Nawar Touma Jason Hu Sylvie Perreault Armen G Aprikian Source Type: research
